GLP-1 RA
Showing 1 - 25 of >10,000
Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)
Not yet recruiting
- Obesity
- +16 more
- ESG
- GLP1-RA
-
Boston, MassachusettsBrigham and Women's Hospital
Nov 14, 2023
Type 2 Diabetes, Diabetes, Type 2 Trial (Tirzepatide)
Not yet recruiting
- Type 2 Diabetes
- Diabetes Mellitus, Type 2
- (no location specified)
Feb 6, 2023
Type 1 Diabetes Trial in Kuwait City (drug, other, procedure)
Not yet recruiting
- Type 1 Diabetes
- Liraglutide / Semaglutide
- +4 more
-
Kuwait City, Al Asimah, KuwaitDasman Diabetes Institute
Jan 8, 2023
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Recruiting
- Type 2 Diabetes Mellitus
- Cardiovascular Diseases
- SU
- +13 more
-
Oakland, California
- +5 more
Oct 18, 2022
Cystic Fibrosis, Cystic Fibrosis-related Diabetes Trial in Minneapolis (Semaglutide)
Not yet recruiting
- Cystic Fibrosis
- Cystic Fibrosis-related Diabetes
-
Minneapolis, MinnesotaUniversity of Minnesota
Mar 15, 2023
Glucagon-Like Peptide-1 Receptor, Metformin, Obesity, Abdominal Trial in Shanghai (Liraglutide, Semaglutide, Metformin)
Recruiting
- Glucagon-Like Peptide-1 Receptor
- +7 more
- Liraglutide
- +2 more
-
Shanghai, Shanghai, ChinaRen Ji Hospital, Shanghai Jiao Tong University School of Medicin
Mar 9, 2023
Diabetes, Diabetic Kidney Disease Trial in Sha Tin (Dulaglutide, Insulin Degludec, Continuous glucose monitor)
Recruiting
- Diabetes Mellitus
- Diabetic Kidney Disease
- Dulaglutide
- +2 more
-
Sha Tin, Hong KongPrince of Wales Hospital
Nov 8, 2022
Cardiovascular Diseases, Diabetes Trial in Boston (SGLT2 inhibitor, GLP-1 RA, Education-First)
Completed
- Cardiovascular Diseases
- Diabetes
- SGLT2 inhibitor, GLP-1 RA
- Education-First
-
Boston, MassachusettsBrigham and Women's Hospital
Sep 13, 2023
Severe Obesity Trial in Minneapolis (Weight loss with pharmacotherapy, Weight loss without pharmacotherapy)
Completed
- Severe Obesity
- Weight loss with pharmacotherapy
- Weight loss without pharmacotherapy
-
Minneapolis, MinnesotaUniversity of Minnesota
Dec 1, 2021
Based on Data From German Sick Funds That Looks at Costs of
Completed
- Diabetes Mellitus, Type 2
- Empagliflozin
- +3 more
-
Ingelheim am Rhein, GermanyBoehringer Ingelheim
Jan 18, 2022
Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility Trial (Intervention to address diffusion of responsibility,
Not yet recruiting
- Diabetes
- +3 more
- Intervention to address diffusion of responsibility
- Intervention to address diffusion of responsibility + simplification of prescribing
- (no location specified)
Jul 14, 2022
Chronic Kidney Diseases Trial in Nashville (dulaglutide injection)
Recruiting
- Chronic Kidney Diseases
- dulaglutide injection
-
Nashville, TennesseeVanderbilt University Medical Center
Mar 20, 2022
A Pan-European Post-Authorisation Safety Study: Risk of
Not yet recruiting
- Pancreatic Cancer
- Exenatide
- Non-GLP-1 RA based glucose lowering drugs
- (no location specified)
Dec 21, 2022
Diabetes, Type 2, Cardiovascular Diseases Trial in Louisville (Educational Intervention)
Active, not recruiting
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Educational Intervention
-
Louisville, KentuckyHumana
May 13, 2022
Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism Trial in Barcelona (Experimental: GLP1-RA (exenatide)
Recruiting
- Hypopituitarism
- +7 more
- Experimental: GLP1-RA (exenatide) administration
- Control: Placebo administration
-
Barcelona, SpainHospital de la Santa Creu i Sant Pau
Mar 18, 2022
Replication of SEPRA Diabetes Trial in Healthcare Claims Data
Active, not recruiting
- Diabetes Mellitus, Type 2
- New use of semaglutide injection
- New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
-
Boston, MassachusettsBrigham and Women's Hospital
Oct 10, 2022
Type 2 Diabetes Trial in Doral (RGT001-075, Placebo)
Active, not recruiting
- Type 2 Diabetes Mellitus
- RGT001-075
- Placebo
-
Doral, FloridaAxon Clinical Research
May 17, 2022
Type 2 Diabetes Trial in Copenhagen (Endurance exercise training, Semaglutide)
Recruiting
- Type 2 Diabetes
- Endurance exercise training
- Semaglutide
-
Copenhagen, DenmarkXlab, Center for Healthy Aging, Department of Biomedical Science
Feb 8, 2021
Metabolic Disturbance, Schizophrenia, Type 2 Diabetes Trial in Copenhagen (Semaglutide, 1.34 mg/mL, Semaglutide-)
Not yet recruiting
- Metabolic Disturbance
- +5 more
- Semaglutide, 1.34 mg/mL
- Semaglutide-placebo
-
Copenhagen, DenmarkPsychiatric Center Copenhagen, Rigshospitalet
Jun 30, 2021
Gastric Volume in Patients on GLP-1 Medications
Recruiting
- Diabetes
- None - observational
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jun 6, 2023
Diabetes, Type 2 Trial in Kuwait (GLP-1 receptor agonist)
Recruiting
- Diabetes Mellitus, Type 2
- GLP-1 receptor agonist
-
Kuwait, KuwaitDasman Diabetes Institute
Jul 19, 2020
Morbid Obesity, Metabolic Syndrome, Diabetes Trial in Columbia (GLP-1 receptor agonist)
Not yet recruiting
- Morbid Obesity
- +4 more
- GLP-1 receptor agonist
-
Columbia, MissouriUniversity of Missouri Hospital
Nov 20, 2023
Four Second Line Pharmacological Strategies in Type 2 Diabetes
Active, not recruiting
- Cardiovascular Events
- +2 more
- SGLT2 inhibitor
- +3 more
-
Boston, MassachusettsBrigham and Women's Hospital
Feb 17, 2022